Advertisement
UK markets open in 3 hours 2 minutes
  • NIKKEI 225

    39,369.62
    -224.77 (-0.57%)
     
  • HANG SENG

    17,368.88
    -100.48 (-0.58%)
     
  • CRUDE OIL

    77.27
    +0.31 (+0.40%)
     
  • GOLD FUTURES

    2,417.90
    +10.60 (+0.44%)
     
  • DOW

    40,358.09
    -57.35 (-0.14%)
     
  • Bitcoin GBP

    51,236.51
    -1,139.51 (-2.18%)
     
  • CMC Crypto 200

    1,361.99
    -23.27 (-1.68%)
     
  • NASDAQ Composite

    17,997.35
    -10.22 (-0.06%)
     
  • UK FTSE All Share

    4,479.49
    -15.97 (-0.36%)
     

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., February 20, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

  • TD Cowen Annual Health Care Conference on Tuesday, March 5 at 12:50pm Eastern Time

  • Leerink Partners Global Biopharma Conference on Tuesday, March 12 at 10:00am Eastern Time

  • Barclays Annual Global Healthcare Conference on Wednesday, March 13 at 11:15am Eastern Time

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

ADVERTISEMENT

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220712986/en/

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com